Autopsy report · NCT01320280

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

“unexpectedly slow recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 6 months before it stopped.
• 29 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Universitätsklinikum Hamburg-Eppendorf

Sponsor type

University, hospital or other

Conditions

Refractory Cancer

Interventions

BIBW 2992 (Afatinib)

Participants

29

Sites

1

Countries

Germany

Trials that died the same way

• Feasibility Study of Navigated Endoscopy for the Placement of High Dose Rate Brachytherapy Applicators in the Esophagus and Lung
  “Slow recruitment” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.